Investing.com – BofA Securities raised its price target on Erasca Inc (NASDAQ:ERAS) to $9.00 from $2.00 while maintaining an Underperform rating on the stock. The stock currently trades at $19.15, well above BofA’s new target, and InvestingPro analysis suggests the shares are overvalued relative to Fair Value estimates. Despite this, the stock has delivered a remarkable 1,268% return over the past year.
The price target increase follows data released for ERAS-0015, the company’s pan-RAS inhibitor. The firm updated its model with higher probability of success and revised market projections.
BofA noted that Erasca held $434 million in cash in its fourth quarter 2025 report. The company maintains strong liquidity with a current ratio of 10.04, though InvestingPro Tips indicate analysts do not anticipate profitability this year. For deeper insights into ERAS’s financial health and 8 additional ProTips, visit InvestingPro. The company is developing ERAS-0015 for pancreatic ductal adenocarcinoma and non-small cell lung cancer.
The firm cited questions about the translatability of China data to the U.S. setting and durability of responses. BofA also noted that safety data from China was not presented, including a reported pneumonitis case and death.
Revolution Medicines, identified as a key pan-RAS competitor, spends more than $1 billion annually on operating expenses and continues to accumulate data and pivotal trial experience across treatment settings.
In other recent news, Erasca, Inc. has announced preliminary Phase 1 dose escalation data for its investigational cancer drug, ERAS-0015. This data comes from the ongoing AURORAS-1 trial in the U.S. and the JYP0015M101 trial in China, which are evaluating the drug’s effectiveness in patients with RAS-mutant solid tumors. Erasca has updated its timeline for the Phase 1 clinical data readout, now expecting results by mid-May 2026, a shift from the previously planned first half of 2026. Meanwhile, Stifel has raised its price target for Erasca to $30, maintaining a Buy rating, following discussions with the company’s CEO and CFO. Additionally, Jefferies has reiterated its Buy rating on Erasca with a $21 price target, noting the potential significance of the upcoming ASCO 2026 conference for the company. The trials for ERAS-0015 are sponsored by Joyo Pharmatech Co., Ltd., which is also conducting a trial in China focused on advanced solid tumors with specific RAS mutations. These developments highlight the ongoing interest and investment in Erasca’s RAS program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Source:
www.investing.com
